



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John P. Devlin

S.N. 10/ 773,903

Filed: February 6, 2004

Entitled: DERIVATIVES OF PENTACYCLIC NORTRITERPENE QUINONE
METHIDES AS COMPOUNDS USEFUL IN THE TREATMENT OF
INFLAMMATORY, NEURODEGENERATIVE AND NEOPLASTIC
DISEASES.

Confirmation Number: 8342

Mail Stop: Missing Parts

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450


RESPONSE

Dear Sir:

In response to the Notice to File Corrected Application Papers, which notice was mailed May 5th, 2004, enclosed please find a substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3) and 1.125. A copy of the Notice to File Corrected Application Papers is also included. Additionally, an abstract of the disclosure is enclosed.

Applicant, through his attorney, hereby states that the enclosed substitute specification does not encompass any new matter, but is simply the application as filed on February 6th, 2004, in the format dictated by 37 CFR.

Respectfully submitted by



.....
Mary-Ellen M. Devlin
Reg. No. 27,928
June 30th, 2004

Enclosures

275 Wewaka Brook Road
Bridgewater, CT 06752
Tel: 860-354-8485